ip investor
Post on 07-May-2015
3.644 Views
Preview:
TRANSCRIPT
Revolutionizing Vaccines
Dr. J. Joseph Kim President & CEO
Forward Looking Statement
Our commentary and responses to your questions may contain forward-looking statements, including comments concerning clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio’s technology by potential corporate partners, capital market conditions, timing of events, cash consumption and other subjects. Information concerning factors that could cause actual results to differ materially from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013 and other regulatory filings from time to time.
2
3
Overview
Inovio’s Technology
4
Plasmids
Electroporation device
• DNA vaccines
• Electroporation delivery
• Best-in-class immune responses
• Favorable safety profile
• Over 400 patents
Products
5
• Targeting cancers and infectious diseases
• Multi-billion dollar healthcare markets
• Lead program for
HPV-caused disease in phase II
• First efficacy data in Q1 2014
• Multiple clinical trials in phase I
Validation
6
• Advancing partnering discussions with large pharma
• Gates-funded malaria program
• US gov’t $25M grant for HIV vaccine development
• NIH Director: “Transformational Research” grant • Almost $50 million in
non-dilutive grants in past few years
Strategy
7
• Establish product proof-of-principle with phase I and II clinical trials
• Spread cost/risk & advance development & commercialization: o R&D grants
o “Sponsored”
clinical trials
o Partnerships
Why Revolutionize Vaccines?
8
Stimulating the Immune System: A Powerful Legacy
• 1776: concept of “modern” vaccination
• Effective vaccines
against 20+ diseases cowpox anthrax
polio
measles Edward Jenner Louis Pasteur Maurice Hilleman
9
#1 Medical Invention
10
INFANT MORTALITY RATE
WORLDWIDE LIFE EXPECTANCY
• Reduced child mortality
• Increased life span
• Protected billions from sickness and death
11
Extending the Legacy
• Concept of stimulating immune system as relevant today as ever
• Can we create 21st century technology to fight today’s cancers & challenging infectious diseases?
• Yes!
How do we Revolutionize Vaccines?
12
Immune Stimulation in the 21st Century
13
• Synthetic • Not a
weakened, killed, or part of a virus
• Therapeutic
• Not preventive only
• Universal
• Not protective against only a single, matched strain
14
Inovio’s Synthetic DNA Vaccines
• Contain DNA code for target disease antigen(s)
• Body produces antigen
• Cannot replicate
• Closest to body’s natural
immune response
• Preventive antibodies • Therapeutic T-cells
• Formulated in water • Stable at room temp
Immune response to last century conventional vaccine
antibodies
Immune response to 21st century DNA vaccine
T-cells
antibodies
15
Novel Consensus Design
• Use gene sequences from multiple strains or types of target disease antigen
• Create new antigen DNA
sequence to help the body recognize: • “Self” made cancer
cells
• Break tolerance
• Similar but unmatched strains
• Universal, cross-strain protection
• Novel DNA sequences
patentable
Differentiate Cancer Cells from “self”
Multi-strain protection within Pathogen families
New synthetic consensus sequence
Multiple unique strains
Break Tolerance Universal Protection
Efficient DNA Vaccine Manufacturing
16
• DNA plasmid production
• Bacterial fermentation process
• Efficient, fast, cost effective, scalable
DNA Delivery: Electroporation
Electric fields applied Vaccine injection
• Overcome two decade hurdle of DNA delivery
• Millisecond electric pulses create pores in cells
• Increase vaccine
uptake 1000X
• Enables cells to produce target antigen
• Widest and deepest global patent estate
17
Cellular vaccine uptake Cell produces coded antigen
18
Raising the Bar: Best in Class Immune Responses
Functional T-Cell Responses
• Highest magnitude of T-cell responses
• 83% response rate in highest dose group
• 92% of responders showed 9 month durability
• 91% of responders showed killing effect against target cells
• HIV study: 89% response rate with robust T-cells
19
Universal Immune Responses
20
• Protective HAI titers in humans against 9 unmatched strains of H1N1 flu from last 100 years
• Strong HAI titers in humans against 6 unmatched strains of deadly H5N1 flu
• Protection against
newly emergent, pandemic-potential H7N9 influenza in mice challenge study
Conventional vaccine: single matched strain only
DNA vaccine: multiple unmatched strains
Preclinical Phase I Phase II
Product Pipeline indication milestone
INOVIO STUDIES
INTERNALLY FUNDED EXTERNALLY FUNDED
Cervical dysplasia THERAPEUTIC
HIV PREVENTIVE/THERAPEUTIC
influenza PREVENTIVE
Hepatitis C THERAPEUTIC
Malaria PREVENTIVE
1Q 2014 Phase II study data
2013 Initiate PENNVAX-GP Phase I study
2013 Phase I data reported
4Q 2013 Initiate Phase I/IIa
2014 Initiate Phase I/IIa
Inovio’s Lead Program
• VGX-3100: therapeutic vaccine • HPV-caused pre-cancers &
cancers • Phase II • First efficacy data: 1Q 2014
22
23
Cervical Cancer 12,357 new cases 3,909 deaths
CIN 2/3 dysplasia 300-400K new cases
CIN 1 dysplasia 1.4M new cases
Head & neck cancer (HPV Related) 8,380 new cases 7,922 deaths (oropharyngeal only)
Anogenital cancers (HPV related ) - Excluding cervical
7,931 new cases 2,396 deaths
U.S. Market opportunity ~ 70% of high risk cervical pre-cancers & cancers caused by HPV Type 16 and 18
Therapeutic HPV
VGX-3100
Therapeutic HPV
• Diseases caused by HPV Type 16 and 18; Target antigens: E6 and E7
• 18 “healthy” patients with
prior CIN 2/3 dyplasia
• Robust immediate T-cell response, average across dose groups/78%
• Dose response
• 92% of responders showed 9 month durability
• 91% with killing effect
• Safe & well tolerated
24
Phase I Trial
Results
Next steps
Therapeutic HPV
Efficacy data expected 1Q 2014
• 148 patients with CIN 2/3 • Randomized, double-blinded,
placebo controlled
• More than 25 sites in 7 countries
• Primary endpoint: lesion clearance within 9 months
25
Phase II Trial
26
HPV Product
Franchise Planning:
• CIN 2/3 phase III
• Other HPV-related indications: initiate phase IIs • Orphan designation potential
Therapeutic HPV
power of our people
• Management • Board of Directors • Scientific Advisory Board
27
Management
anthrax
polio
cowpox
Louis Pasteur
J.Joseph Kim, PhD President & CEO
• Decades of biotechnology/pharma management
• Ex-Merck: hepatitis A and B vaccines manufacturing; HIV vaccine (Ad5) R&D
Niranjan Y. Sardesai, PhD COO
• Extensive biotech management and product development experience
• Led development of diagnostics for mesothelioma, bladder cancer, and ovarian
cancer for Fujirebio Diagnostics
Peter Kies CFO • Ex-Ernst & Young • Experience with growth companies
Mark L. Bagarazzi, MD CMO • Clinical research experience incl. Merck • Led clinical/regulatory for shingles and rotavirus vaccines; DNA vaccine expert
28
Board of Directors
anthrax
polio
cowpox
Louis Pasteur Simon X. Benito
• Former Senior Vice President, Merck Vaccine Division
Angel Cabrera, PhD • President, George Mason University
• Former President, Thunderbird School of Global Management
J.Joseph Kim, PhD • President & CEO, Inovio
Adel Mahmoud, PhD • Professor, Princeton University • Former President, Merck Vaccines • Responsible for Gardasil®, Zostavax®, Proquad® and Rotateq®
Avtar Dhillon, MD Chairman, BOD
• Former President & CEO, Inovio Biomedical
Morton Collins, PhD • General Partner, Battelle Ventures and Innovations Valley Partners
29
Scientific Advisory Board
anthrax
polio
cowpox
Louis Pasteur Thomas S. Edgington, MD
• Founded multiple biotech companies; extensively published
• Emeritus Professor, Scripps Research Institute
Anthony W. Ford-Hutchinson, PhD • Former SVP, Vaccines R&D, Merck
• Oversaw development: Singulair®, Januvia®, Gardasil®, Zostavax®, Proquad® and Rotateq®
Stanley A. Plotkin, MD • Developed rubella and rabies vaccines • Oversaw Sanofi flu vaccine • Emeritus Professor, Wistar Institute & University of Pennsylvania
David B. Weiner, PhD Chairman
•“Father of DNA vaccines” • Dept. of Pathology & Laboratory Medicine,
University of Pennsylvania
Philip Greenberg, MD • Expert in T-cell immunology • Head, Immunology Program, Fred Hutchinson Cancer Research Center
30
1/1/13 2/1/13 3/1/13 4/1/13 5/1/13 6/1/13 7/1/13
financial information
$1.47
31
Financial Information
Cash, cash equivalents & short-term investments1 $ 28.2M
Debt1 0 M
Cash runway 4Q 2014
issued & outstanding shares2 179.9 M
Recent price2 $ 1.47
Market cap2 $ 264.5M
listing Nyse mkt: INO
1March 31, 2013 2 July10, 2013
6/10/13 7/10/13
$1.47
32
33
Investment highlights • Novel vaccine technology platform with
best-in-class immune responses
• Partnering discussions with Big Pharma
• Phase II efficacy data 1Q 2014 • Large opportunity – cancers and
infectious diseases with unmet needs; broad pipeline
• Substantial non-dilutive funding
Bernie Hertel Senior Director, Corporate Communications 858-410-3101 bhertel@inovio.com
Investor Contact
investor contacts
34
top related